Pyxis Oncology (PYXS) Stock

- The Company will focus resources on advancing its lead asset, PYX-201 - PYX-201 is a novel first-in-concept antibody-drug conjugate (ADC) where significant RECIST responses were seen in head and neck squamous cell carcinoma (HNSCC) with additional potential in other solid tumors - Current cash runway expected to fund development into 2H 2026 BOSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a portfolio prioritization, focusing resources on advancing its lead clinical program, PYX-201, a first-in-concept antibody-drug conjugate (ADC) with a microtubule inhibitor (optimized auristatin) payload that uniquely targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component within the tumor extracellular matrix. In November 2024, Pyxis Oncology reported positive preliminary data from the ongoing Phase 1 dose-escalation study of PYX-201, evaluating its safety and efficacy in multiple solid tumor types.

Pyxis Oncology's lead candidate, PYX-201, showed promising response rates in Phase 1 trials but raised safety concerns due to a patient's death. The company's valuation appears deeply discounted, with a P/B ratio of 0.7 compared to a sector median of 2.4, reflecting market pessimism. PYX-201's ongoing trials and upcoming catalysts in 2025-2026 are crucial for addressing safety concerns and demonstrating efficacy across multiple cancer types.

NEW YORK , Sept. 25, 2024 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Pyxis Oncology, Inc. (NASDAQ:PYXS) concerning possible breaches of fiduciary duty.

Pyxis Oncology is an antibody and antibody-drug conjugate developer with initial results from two clinical trials ahead in 2024. Data from a phase 1 study of PYX-201, an ADC targeting extra domain B of fibronectin, in multiple tumor types, are expected in fall 2024. Data from a phase 1 study of PYX-106, an anti-Siglec-15 antibody, in multiple tumor types, are expected by year-end 2024.

BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in fireside chats and members of management will participate in one-on-one meetings at the following two upcoming investor conferences:

BOSTON, July 29, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, and members of management will participate in one-on-one meetings at the BTIG Virtual Biotechnology Conference being held August 5-6, 2024.

Pyxis Oncology, Inc. (PYXS) reported a quarterly loss of $0.06 per share, which was better than the Zacks Consensus Estimate of a loss of $0.27. This is an improvement from the loss of $0.54 per share reported in the same quarter last year.

On Wall Street, analysts' average price targets suggest a potential 61.3% increase in Pyxis Oncology (PYXS). Though the accuracy of this metric is uncertain, the positive trend in earnings estimates could lead to a rise in the stock.

Pyxis Oncology (PYXS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).